186O Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial

Authors :: MARIA VITTORIA DIECI
PIERFRANCO CONTE
Bisagni, G.
A Brandes, A.
Frassoldati, A.
Cavanna, L.
Musolino, A.
Giotta, F.
Rimanti, A.
Garrone, O.
Bertone, E.
Cagossi, K.
Sarti, S.
Ferro, A.
Omarini, C.
Maiorana, A.
Orvieto, E.
Sanders, M.
D Amico, R.
VALENTINA GUARNERI
Source :: Università degli Studi di Padova-IRIS

Tools